PEGylated Proteins Market (By Type: PEGylation kits and reagents; By Product; By Application; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global PEGylated proteins market was surpassed at USD 12,786 million in 2021 and is expected to hit around USD 22,967 million by 2030, growing at a CAGR of 7.2% from 2022 to 2030.

PEGylated Proteins Market Size 2021 to 2030

PEGylation is the process of a combination of polyethylene glycol (both covalent and non-covalent) polymer chains with molecules, proteins, and peptides. This is useful in targeted drug delivery systems and in genetically modifying cells. These molecules have a long half-life (in the bloodstream), reduced toxicity, decreased immunogenicity, and increased proteolytic protection. Separation of the PEGylated proteins is done using chromatography. It includes such as size exclusion chromatography (SEC), hydrophobic interaction chromatography, and electrostatic interaction chromatography (ion-exchange chromatography, IEC). On the other hand, the process cost of the process is comparatively high. Polyethylene glycol is regarded as safe by US FDA for internal administration.

PEGylation of proteins also has pharmacological advantages and significance which include improved drug solubility, reduced dosage frequency, increased drug stability, and minimum loss of biological activity. Some of FDA approved pegylated drugs are Cimzia, Mircera, Macugen, Somavert, Pegasys, and Neulasta. These drugs are useful to treat various diseases like Crohn’s disease, anemia in chronic kidney disease, age-related macular degeneration, Acromegaly, hepatitis C, and Neutropenia during chemotherapy. PEG molecules in the conjugation of nanoparticles are used in the advanced drug-delivery systems for anti-cancer therapy.

The research on PEGylated protein drugs focuses on adenosine deaminase, asparaginase, interferons, granulocyte colony-stimulating factor, interleukins, etc. Recently JenKem Technology is the large-scale manufacturer of PEG derivatives of lipid nanoparticles and other intermediates. Increased incidence of cancer and delay in the diagnosis is been observed all over the globe as per the research of JCO Clinical Cancer Informatics in the U.S. The awareness among the patients and healthcare professionals is observed for the adverse effects of cancer treatments like chemotherapy. So the major focus for alternative therapeutics treatment like pegylated peptide-based drugs, colony-stimulating factors is the driving factor for the growth of the market in the forecast years.

The PEGylated protein market is segmented based on product type, protein type, application, end-user, and region. On the basis of product type the market is segmented into consumables and services. Consumables include PEGylation kits and PEGylation reagents. Based on the protein type, the market is segmented based on colony-stimulating factor, interferons, erythropoietin, and recombinant factor VII.

North America dominates the markets due to the rise in the prevalence of chronic diseases like cancer. The cancer treatment estimates the highest CAGR during the forecast period. This is due to the increase in the adoption of new drugs for the treatments like monoclonal antibodies, interferons, and many more. Along with this the increase in government funding, and grants for research projects with the advancements in the field of biotechnology and research and development boost the North American PEGylated Protein Market.

Scope of The Report

Report Coverage Details
Market Size in 2021 USD 12,786 million  
Revenue Forecast by 2030 USD 22,967 million 
Growth rate from 2022 to 2030 CAGR of 7.2%
Base Year 2021
Forecast Period 2022 to 2030
Segmentation Type, Protein, Application, End user, Region
Companies Covered

Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A, AstraZeneca, Amgen, Inc., Biogen, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Coherus Biosciences, Biomarin Pharmaceutical Inc., Enzon, Leadient Biosciences, Inc.


Key Players

  • Thermo Fisher Scientific Inc.
  • Horizon Therapeutics Plc.
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A
  • AstraZeneca
  • Amgen, Inc.
  • Biogen
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Company Limited 
  • Bayer AG
  • Coherus Biosciences
  • Biomarin Pharmaceutical Inc.
  • Enzon
  • Leadient Biosciences, Inc.

Market Segmentation

  • By Type
    •  Consumables
    • Services 
  • By Protein
    • Colony-stimulating factor
    • Interferons
    • Erythropoietin
    • Recombinant factor VII
    • Other protein types
  • By Application
    • Cancer (nanoparticles associated drug delivery system)
    • Autoimmune Disease (Telerogenic Immunomodulation by PEGylated Antigenic peptides)
    • Hepatitis (PEGylated interferons)
    • Multiple Sclerosis (PEGylated interferon beta)
    • Hemophilia
    • Gastrointestinal Disorder (Inflammatory bowel disease-PEGylation on antibody loaded NPs)
    • Others
  • By End user
    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organizations
    • Academic Research Institutes
  • By Region
    • North America 
    • Europe 
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Report Detail

Proceed To Buy

USD 4500
USD 7900

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers